Physician profile
Hani H Hashem
NPI 1033179379
$2,242.54
in general payments reported to CMS, 2019-2025
16 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $156 · 2021: $583 · 2022: $571 · 2023: $282 · 2024: $97.57 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $763.86 | 2019-2024 | Otezla |
| Abbvie INC. | $352.83 | 2021-2025 | |
| Novo Nordisk INC | $351.20 | 2021-2022 | |
| Stryker Corporation | $161.11 | 2022 | |
| Genzyme Corporation | $127.62 | 2019 | |
| Horizon Therapeutics Plc | $123.78 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.35 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $61.14 | 2023 | Quviviq |
| Edwards Lifesciences Corporation | $52.34 | 2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $31.91 | 2020-2021 | |
| Lilly USA, LLC | $31.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.62 | 2021 | |
| Dexcom, INC. | $28.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.80 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $15.67 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hani Hashem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.